MYCN and neuroblastoma: Four patients diagnosed with neuroblastoma could be stratified based on RNA-seq and CNV: one high-risk patient with MYCN amplification, LOH at 1p and 11q, gain of 17q, and MYCN overexpression; one high-risk patient with MYCN amplification, LOH at 1p, gain of 17q, and MYCN overexpression; one high-risk patient without MYCN amplification or LOH at 1p and 11q, and no evidence of MYCN overexpression; and one intermediate-risk patient without MYCN amplification or LOH at 1p and 11q and no evidence of MYCN overexpression.